HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: gut.2007.130252v1 57/3/344    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Serba, S Articles by Märten, A Search for Related Content PubMed PubMed Citation Articles by Serba, S Articles by Märten, A Topic Collections Relevant Article

Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma

¹ Department of Surgery, University of Heidelberg, Heidelberg, Germany
² Department of Pathology, University of Heidelberg, Heidelberg, Germany
³ National Centre for Tumour Diseases, University of Heidelberg, Heidelberg, Germany

Correspondence to:
Professor Angela Märten, Department of Surgery, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany; angela.maerten{at}med.uni-heidelberg.de

Objective: Patients with adenocarcinoma of the pancreas have only limited promising therapy options. Therefore, immunotherapeutic approaches might be considered promising and have gained importance over the last few years. In this study, CD40L gene transfer was tested as potent immunotherapy.

Methods: The efficacy of CD40L gene transfer in initiating anti-tumour immune response was investigated in a pancreatic ductal adenocarcinoma orthotopic syngeneic mouse model. In addition, the role of dendritic cells was determined.

Results: A significantly slower tumour growth rate and less metastasis were observed following administration of the CD40L plasmid. Such an effect of the plasmid was not observed in immunodeficient mice. Tumours of treated mice were found to be infiltrated with T cells and dendritic cells. The latter were mature and of myeloid origin. Tumour-infiltrating lymphocytes were tumour-specific as shown in IFN- ELISPot assays. Using intravital microscopy it was possible to show a significant induction of leukocytes sticking to the tumour endothelium after CD40L treatment. Adoptive cell transfer experiments have revealed that tumour-derived dendritic cells and CD8 cells from CD40L-treated donor mice either harbour anti-tumour activity or induce it in the recipients. Distinctly, CD8 cells from donor spleens were found to migrate directly into the recipient’s tumour.

Conclusions: The induction of anti-tumour activity initiated after treating mice with the CD40L plasmid was achieved. Further investigations showed that this is mediated by mature myeloid dendritic cells which activate CD8 cells. Clinical trials investigating CD40L-based therapies should be extended.

This article has been cited by other articles:

				K. C. Bagley Genetic adjuvant therapy for pancreatic cancer and other solid tumours Gut, March 1, 2008; 57(3): 289 - 291. [Full Text] [PDF]